Quantum BioPharma Q2 net loss narrows to USD 3.09 million; operating loss improves to USD 2.29 million

PUBT · 1d ago
Quantum BioPharma Q2 net loss narrows to USD 3.09 million; operating loss improves to USD 2.29 million
  • Quantum Biopharma posted a net loss of USD 16.85 million for the six months ended June 30, 2026, compared with USD 18.51 million a year earlier.
  • Loss per share narrowed to USD 3.02 from USD 6.73 in the prior-year period.
  • Cash used in operating activities improved to USD 3.46 million from USD 6.21 million in the prior-year period.
  • Digital assets rose to USD 5.89 million at June 30, 2026, while cash and cash equivalents increased to USD 3.65 million.
  • Trade and other payables declined to USD 3.38 million from USD 4.18 million at Dec. 31, 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001185185-26-003497), on August 13, 2026, and is solely responsible for the information contained therein.